CT Colonography Cost-Effective, Clinically Effective for CRC Screening
By Elana Gotkine HealthDay Reporter
MONDAY, June 16, 2025 -- Computed tomography colonography (CTC) is cost-effective and clinically effective for colorectal cancer (CRC) screening, according to a study published online June 10 in Radiology.
Perry J. Pickhardt, M.D., from the University of Wisconsin School of Medicine & Public Health in Madison, and colleagues compared the clinical efficacy and cost-effectiveness of CRC screening with CTC versus multitarget stool DNA (mt-sDNA) testing. Using updated natural history evidence for colorectal polyps applied to a hypothetical 10,000-person cohort representative of the 45-year-old U.S. population, a Markov model was constructed. Three screening strategies were modeled with these data: mt-sDNA testing every three years, conventional CTC (CTCconv), and surveillance CTC (CTCsurv) strategies. The CTCconv strategy involved immediate polypectomy for all polyps measuring at least 6 mm every five years, whereas the CTCsurv strategy involved three-year CTC follow-up for small polyps measuring 6 to 9 mm and polypectomy for polyps ≥10 mm.
The researchers found that the cumulative incidence of CRC was 7.5 percent without screening, which was reduced by 59, 75, and 70 percent with mt-sDNA, CTCconv, and CTCsurv, respectively. The estimated programmatic costs were $4,955, $6,011, $4,422, and $3,913 for no screening, mt-sDNA, CTCconv, and CTCsurv, respectively. Per quality-adjusted life-year (QALY) gained, the estimated cost was $8,878 for mt-sDNA, while both CTC strategies were cost-saving; consequently, CTC strategies dominated over mt-sDNA and no screening. The CTCconv strategy was less cost-effective than the CTCsurv strategy, with costs associated with more optical colonoscopies not offsetting the small gains in QALYs. When CRC screening began at ages 50 and 65 years, the results were similar.
"Among the safe, minimally invasive colorectal cancer screening options, CT colonography is more effective at preventing and detecting cancer -- and is also more cost-effective -- than stool DNA testing," Pickhardt said in a statement.
Several authors disclosed ties to the biotechnology and medical technology industries, including Bracco Diagnostics, which partially funded the study.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-06-17 06:10
Read more

- AI Boosts Skin Cancer Diagnoses, Study Says
- CDC Vaccine Expert Resigns After RFK Jr. Cuts Advisers
- Alcohol-Linked Liver Deaths Rising in Women and Young Adults
- Hydrops MRI Accurately Differentiates Meniere Disease, Vestibular Migraine
- Generative AI Model for Draft Radiological Reporting Improves Documentation Efficiency
- Novo Nordisk to Advance Subcutaneous and Oral Amycretin for Weight Management Into Phase 3 Clinical Development
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions